SCHEMBL4501787

SCHEMBL4501787

CCN(C(=O)CN1CCN(C)CC1)c1ccc(NC(=C2C(=O)Nc3cc(Cl)ccc32)c2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 3/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
GHSR Q92847 4/20 0.38
PIM1 P11309 2/20 0.38
PIM2 Q9P1W9 2/20 0.38
AAK1 Q2M2I8 1/20 0.38
LMNA P02545 3/20 0.37
TDP1 Q9NUW8 2/20 0.36
TP53 P04637 2/20 0.36
HTT P42858 1/20 0.36
POLB P06746 1/20 0.36
GFER P55789 1/20 0.36
GAA P10253 1/20 0.35
TERT O14746 1/20 0.35
PLK1 P53350 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501785 1.00 SMN1; SMN2 (0.43) SMN1; SMN2MAPTALDH1A1KDM4ETSHR
SCHEMBL4497385 0.94 SMN1; SMN2 (0.42) SMN1; SMN2MAPTALDH1A1KDM4ETSHR
SCHEMBL4497388 0.94 SMN1; SMN2 (0.42) SMN1; SMN2MAPTALDH1A1KDM4ETSHR
SCHEMBL4501911 0.93 SMN1; SMN2 (0.41) SMN1; SMN2MAPTALDH1A1GHSRPIM1
SCHEMBL4501915 0.93 SMN1; SMN2 (0.41) SMN1; SMN2MAPTALDH1A1GHSRPIM1
SCHEMBL4501594 0.92 SMN1; SMN2 (0.42) SMN1; SMN2MAPTALDH1A1KDM4ETSHR
SCHEMBL4501589 0.92 SMN1; SMN2 (0.42) SMN1; SMN2MAPTALDH1A1KDM4ETSHR
SCHEMBL4504806 0.92 SMN1; SMN2 (0.41) SMN1; SMN2MAPTALDH1A1GHSRPIM1
SCHEMBL4485830 0.92 SMN1; SMN2 (0.41) SMN1; SMN2MAPTALDH1A1GHSRPIM1
SCHEMBL4504800 0.92 SMN1; SMN2 (0.41) SMN1; SMN2MAPTALDH1A1GHSRPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR SMN1; SMN2 4006/4885MAPT 545/4885ALDH1A1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.